---
title: "CIRC's subsidiary's application for clinical trials of improved new drugs has been approved"
description: "The clinical trial application for the improved new drug \"Injection Boron [10B] Falan\" developed by China CIRC's subsidiary China Nuclear Huadewei has been approved by the National Medical Products Ad"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270402848.md"
published_at: "2025-12-21T11:17:04.000Z"
---

# CIRC's subsidiary's application for clinical trials of improved new drugs has been approved

> The clinical trial application for the improved new drug "Injection Boron [10B] Falan" developed by China CIRC's subsidiary China Nuclear Huadewei has been approved by the National Medical Products Administration. This drug has significant clinical advantages for head and neck tumors, with a short treatment course and low toxicity

China National Nuclear Corporation (01763.HK) announced that the information on the official website of the National Medical Products Administration shows that the clinical trial application for the 2.2 class improved new drug "Injectable Boron \[10B\] Fen" (BNCT boron drug: Boron Neutron Capture Therapy), independently developed by its subsidiary China Nuclear Haidewei, has been approved.

"Injectable Boron \[10B\] Fen" has significant clinical advantages for head and neck tumors that are insensitive to radiotherapy and chemotherapy, recurrent, refractory, infiltrative, in the middle to late stages, and locally metastatic, with a short treatment course (only requiring 1-2 sessions) and low toxicity and side effects

### Related Stocks

- [01763.HK - CIRC](https://longbridge.com/en/quote/01763.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China Isotope & Radiation Corporation and CNNC Capital Sign Strategic Cooperation Agreement | China Isotope & Radiation Corporation (CIRC) and CNNC Capital Holdings Limited have signed a strategic cooperation agree | [Link](https://longbridge.com/en/news/267624056.md) |
| Henlius Biotech Get China Nod for Trial Application of Multiple Myeloma Drug | Henlius Biotech Get China Nod for Trial Application of Multiple Myeloma Drug | [Link](https://longbridge.com/en/news/275731047.md) |
| 23:18 ETNovel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF | Shanghai Ark Biopharmaceutical Co., Ltd. announced that the FDA has cleared its IND application for AK3280, a novel anti | [Link](https://longbridge.com/en/news/275698481.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/en/news/275851575.md) |
| Hi Sun Technology to Record HK$100 Million Impairment Loss on Megahunt Investment | Hi Sun Technology (China) Limited anticipates a non-cash impairment loss of approximately HK$100 million on its investme | [Link](https://longbridge.com/en/news/275584607.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.